- Home
- GEN vs ROIV Comparison
GEN vs ROIV Comparison
Compare GEN & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GEN | ROIV |
|---|---|---|
| Founded | 1982 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GEN | ROIV |
|---|---|---|
| Price | $26.94 | $21.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $35.43 | $21.19 |
| AVG Volume (30 Days) | 5.3M | ★ 7.1M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $4,473,000,000.00 | $20,329,000.00 |
| Revenue This Year | $26.99 | N/A |
| Revenue Next Year | $4.88 | $376.94 |
| P/E Ratio | $29.64 | ★ N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $22.74 | $8.73 |
| 52 Week High | $32.22 | $21.35 |
Technical Indicators
Market Signals| Indicator | GEN | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 53.83 | 65.67 |
| Support Level | $25.97 | $19.96 |
| Resistance Level | $26.82 | $20.99 |
| Average True Range (ATR) | 0.57 | 0.62 |
| MACD | 0.12 | -0.13 |
| Stochastic Oscillator | 75.94 | 88.32 |
Price Performance
Historical ComparisonAbout GEN Gen Digital Inc.
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.